Dominik Hartl,
Chief Medical Officer

Dominik joined Granite-Bio in 2022 with a background in Immunology & Fibrosis Drug Development. Prior to Granite-Bio, Dominik served as CMO for QUELL Therapeutics, London, UK.

Earlier in his career, Dominik held leadership positions in Immunology Drug Development/Translational Medicine at Novartis (NIBR/ATI), Roche (pRED/I2O) and Galapagos Pharma.

Dominik obtained his M.D. and doctoral thesis degree at the Ludwig-Maximilians-University (LMU) Munich. He is a board-certified Pediatrician and worked as physician scientist at Yale University, LMU Munich, University of Tübingen & Sanquin Research Center Amsterdam. Dominik holds an adjunct Professorship at University of Tübingen (Pediatric Immunology) and is actively publishing in the autoimmunity and translational medicine space.

For more information: https://www.linkedin.com/in/dominik-hartl-md-5a2b3bb4/